Vitrolife AB (publ) – Fourth quarter and full year report 2025

GOTHENBURG, Sweden, Feb. 3, 2026 /PRNewswire/ — 

Fourth quarter 

• Sales of SEK 891 (959) million, organic growth in local currencies excluding discontinued business* were 6%, 3% growth in local currencies and 7% decrease in SEK, due to a significant currency impact of -10%.
• Sales per region, in local currencies, were -1% in EMEA excluding discontinued business, +9% in Americas and +10% in APAC.
• Sales per product group, in local currencies excluding discontinued business, were +10% in Consumables, +6% in Technologies and +1% in Genetics.
• Gross margin decreased to 58.0% (61.1). Gross margin excluding restructuring costs was 58.6% (61.1).
• Earnings before depreciation and amortisation (EBITDA) amounted to SEK 196 (337) million, resulting in an EBITDA margin of 22.0% (35.1). EBITDA excluding restructuring costs amounted to SEK 251 (337) million, resulting in an EBITDA margin of 28.2% (35.1) impacted by negative currency effect.
• Restructuring costs of SEK 55 million whereof SEK 6 million in COGS and SEK 49 million in operating expenses.
• An impairment charge of SEK 5,357 million was reported as other operating expenses.
• Net income amounted to SEK -5,314 (139) million, resulting in earnings per share of SEK -39.24 (1.02). Net income excluding the impairment charge and restructuring costs amounted to SEK 89 million (139), resulting in earnings per share of SEK 0.66 (1.02).
• Operating cash flow amounted to SEK 160 (268) million.

Full year

• Sales of SEK 3,440 (3,609) million, organic growth in local currencies excluding discontinued business was 4%, 2% growth in local currencies and 5% decrease in SEK, due to a significant currency impact of -6%.
• Sales per region, in local currencies, were +5% in EMEA excluding discontinued business, +8% in Americas and -1% in APAC.
• Sales per product group, in local currencies excluding discontinued business, were +8% in Consumables, +1% in Technologies and +3% in Genetics.
• Gross margin decreased to 58.1% (59.3). Gross margin excluding restructuring costs was 58.2% (59.3).
• Earnings before depreciation and amortisation (EBITDA) amounted to SEK 949 (1,225) million, resulting in an EBITDA margin of 27.6% (34.0). EBITDA excluding restructuring costs amounted to SEK 1,004 (1,225) million, resulting in an EBITDA margin of 29.2% (34.0) significantly impacted by negative currency effect.
• Restructuring costs of SEK 55 million whereof SEK 6 million in COGS and SEK 49 million in operating expenses.
• An impairment charge of SEK 5,357 million was reported as other operating expenses.
• Net income amounted to SEK -5,013 (514) million, resulting in earnings per share of SEK -37.01 (3.78). Net income excluding the impairment charge and restructuring costs amounted to SEK 390 million (514), resulting in earnings per share of SEK 2.89 (3.78).
• Operating cash flow amounted to SEK 635 (907) million.

Dividend

• The Board to propose to the Annual General Meeting a dividend of SEK 149 (149) million, corresponding to SEK 1.10 (1.10) per share.
  * Discontinued business refers to discontinued activities in certain markets in EMEA.

Gothenburg, February 3, 2026 
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO

This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 03-02-2026 08:00 CET.

CONTACT:

Amelie Wilson,
Investor relations,
external corporate communications and executive support, 
[email protected] 

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/vitrolife-ab–publ-/r/fourth-quarter-and-full-year-report-2025,c4301569

The following files are available for download:

View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-publ—fourth-quarter-and-full-year-report-2025-302677313.html

SOURCE Vitrolife AB (publ)